HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kropp, J. Articles by Biersack, H.-J. Search for Related Content PubMed PubMed Citation Articles by Kropp, J. Articles by Biersack, H.-J.

Inhalation of [¹²³I]₁-Protease Inhibitor: Toward a New Therapeutic Concept of ₁-Protease Inhibitor Deficiency?

Department of Nuclear Medicine, University Hospital of Technische Universität Dresden, Dresden; Department of Pneumology, University Hospital Essen, Ruhrlandklinik, Essen; Nuclear Medicine, Mainz-Kastel, Mainz; Bayer Vital, Leverkusen; Pharma Research Center, Bayer AG, Wuppertal; and Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany

View larger version (10K): [in a new window]   FIGURE 1. UV absorption of HPLC of radiolabeled 123I-1-Pi with cold iodinated 1-Pi added as standard 1 and 30 h after labeling. Bottom shows HPLC of human serum albumin (HSA), revealing same retention time as for 1-Pi, as expected.

View larger version (12K): [in a new window]   FIGURE 2. Same analysis as in Figure 1, but data of flow through radioactivity (RA) detector are shown along with 123I. Same retention time as shown on UV scan is obvious for radioiodinated 1-Pi, indicating stable radioiodinated compound.

View larger version (94K): [in a new window]   FIGURE 3. Gamma camera scintigrams immediately after inhalation and 1, 4, and 24 h after inhalation (columns from left to right, respectively) for one patient from each of groups I, II, and III (rows from bottom to top, respectively).